JP2016531158A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016531158A5 JP2016531158A5 JP2016542879A JP2016542879A JP2016531158A5 JP 2016531158 A5 JP2016531158 A5 JP 2016531158A5 JP 2016542879 A JP2016542879 A JP 2016542879A JP 2016542879 A JP2016542879 A JP 2016542879A JP 2016531158 A5 JP2016531158 A5 JP 2016531158A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- administered
- eculizumab
- dose
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960002224 eculizumab Drugs 0.000 claims description 13
- 210000002966 serum Anatomy 0.000 claims description 3
- 102000012192 Cystatin C Human genes 0.000 claims description 2
- 108010061642 Cystatin C Proteins 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 16
- 239000003795 chemical substances by application Substances 0.000 claims 15
- 230000004044 response Effects 0.000 claims 9
- 230000002489 hematologic effect Effects 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 6
- 238000005259 measurement Methods 0.000 claims 6
- 210000003743 erythrocyte Anatomy 0.000 claims 5
- 230000006698 induction Effects 0.000 claims 5
- 108090000790 Enzymes Proteins 0.000 claims 4
- 102000004190 Enzymes Human genes 0.000 claims 4
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 claims 4
- 238000003018 immunoassay Methods 0.000 claims 4
- 206010018910 Haemolysis Diseases 0.000 claims 3
- 241001494479 Pecora Species 0.000 claims 3
- 230000024203 complement activation Effects 0.000 claims 3
- 230000008588 hemolysis Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 238000010606 normalization Methods 0.000 claims 3
- 230000003442 weekly effect Effects 0.000 claims 3
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 2
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 2
- 108060006698 EGF receptor Proteins 0.000 claims 1
- 210000001772 blood platelet Anatomy 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 229940109239 creatinine Drugs 0.000 claims 1
- 230000008034 disappearance Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 230000024924 glomerular filtration Effects 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 239000013610 patient sample Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 201000001474 proteinuria Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000011287 therapeutic dose Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019234471A JP7572777B2 (ja) | 2013-09-16 | 2019-12-25 | Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361878119P | 2013-09-16 | 2013-09-16 | |
| US61/878,119 | 2013-09-16 | ||
| PCT/US2014/055922 WO2015039126A1 (en) | 2013-09-16 | 2014-09-16 | Compositions and methods for treatment of hsct-associated thrombotic microangiopathy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019234471A Division JP7572777B2 (ja) | 2013-09-16 | 2019-12-25 | Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016531158A JP2016531158A (ja) | 2016-10-06 |
| JP2016531158A5 true JP2016531158A5 (cg-RX-API-DMAC10.html) | 2017-11-02 |
| JP6654137B2 JP6654137B2 (ja) | 2020-02-26 |
Family
ID=52666441
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016542879A Active JP6654137B2 (ja) | 2013-09-16 | 2014-09-16 | Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法 |
| JP2019234471A Active JP7572777B2 (ja) | 2013-09-16 | 2019-12-25 | Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法 |
| JP2022014712A Pending JP2022062161A (ja) | 2013-09-16 | 2022-02-02 | Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法 |
| JP2024118532A Withdrawn JP2024133399A (ja) | 2013-09-16 | 2024-07-24 | Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019234471A Active JP7572777B2 (ja) | 2013-09-16 | 2019-12-25 | Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法 |
| JP2022014712A Pending JP2022062161A (ja) | 2013-09-16 | 2022-02-02 | Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法 |
| JP2024118532A Withdrawn JP2024133399A (ja) | 2013-09-16 | 2024-07-24 | Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10815296B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP3046581B1 (cg-RX-API-DMAC10.html) |
| JP (4) | JP6654137B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2921856A1 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2796078T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2015039126A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2796078T3 (es) * | 2013-09-16 | 2020-11-25 | Childrens Hospital Med Ct | Composiciones y métodos para el tratamiento de la microangiopatía trombótica asociada al hsct |
| RS61351B1 (sr) | 2013-10-17 | 2021-02-26 | Omeros Corp | Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2 |
| CN106999559A (zh) * | 2014-12-19 | 2017-08-01 | 儿童医院医疗中心 | 与移植相关血栓性微血管病相关的方法和组合物 |
| WO2016200627A1 (en) * | 2015-06-09 | 2016-12-15 | Children's Hospital Medical Center | Dosing algorithm for complement inhibitor |
| TW201718014A (zh) * | 2015-10-12 | 2017-06-01 | 諾華公司 | C5抑制劑於移植相關微血管病之用途 |
| CN117398458A (zh) * | 2015-11-09 | 2024-01-16 | 奥默罗斯公司 | 用于治疗与masp-2依赖性补体活化相关的病况的方法 |
| IL263481B2 (en) | 2016-06-14 | 2024-06-01 | Regeneron Pharma | Anti-c5 antibodies and uses thereof |
| WO2019108456A1 (en) * | 2017-12-01 | 2019-06-06 | Children's Hospital Medical Center | Compositions for interferon blockade and methods of using same |
| AU2018383751B2 (en) | 2017-12-13 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibody combinations and uses thereof |
| JP2023503776A (ja) * | 2019-09-27 | 2023-02-01 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | 造血幹細胞移植後の血栓性微小血管症（ｈｓｃｔ－ｔｍａ）の治療方法 |
| JP7821160B2 (ja) * | 2020-08-13 | 2026-02-26 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を処置するための抗ｃ５抗体の用量及び投与 |
| US20250066461A1 (en) * | 2021-12-21 | 2025-02-27 | Children's Hospital Medical Center | Compositions and methods for treating transplant associated thrombotic microangiopathy in bleeding patients |
| TW202426048A (zh) * | 2022-09-06 | 2024-07-01 | 美商阿雷希昂製藥公司 | 用於治療造血幹細胞移植相關血栓性（ｈｓｃｔ－ｔｍａ）的抗ｃ５抗體的補充劑量和投與 |
| CA3266977A1 (en) | 2022-09-06 | 2024-03-14 | Alexion Pharmaceuticals, Inc. | DIAGNOSTIC AND PROGNOSIS BIOMARKER PROFILES IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA) |
| WO2024137904A1 (en) * | 2022-12-21 | 2024-06-27 | Children's Hospital Medical Center | Improved eculizumab precision dosing |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040013664A1 (en) | 1997-01-14 | 2004-01-22 | Gentz Reiner L. | Tumor necrosis factor receptors 6 alpha & 6 beta |
| WO2004034988A2 (en) | 2002-10-16 | 2004-04-29 | Amgen Inc. | Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors |
| US20070116710A1 (en) | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
| DK1991275T3 (en) * | 2006-03-08 | 2014-12-08 | Archemix Llc | Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES |
| JP6223659B2 (ja) | 2008-11-10 | 2017-11-01 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体関連障害を処置するための方法および組成物 |
| JP2011178687A (ja) * | 2010-02-26 | 2011-09-15 | Kochi Univ | 造血細胞移植に伴う疼痛の予防および／または治療剤 |
| WO2011109338A1 (en) | 2010-03-01 | 2011-09-09 | Alexion Pharmaceuticals Inc. | Methods and compositions for treating degos' disease |
| SG11201402490XA (en) | 2011-11-23 | 2014-06-27 | Amgen Inc | Methods of treatment using an antibody against interferon gamma |
| CN104870012A (zh) | 2012-06-27 | 2015-08-26 | 吉安特科技公司 | 用于炎性疾病的抗-cxcl9、抗-cxcl10、抗-cxcl11、抗-cxcl13、抗-cxcr3和抗-cxcr5试剂 |
| AU2014306002B2 (en) | 2013-08-07 | 2017-05-25 | Alexion Pharmaceuticals, Inc. | Atypical hemolytic uremic syndrome (aHUS) biomarker proteins |
| US10254288B2 (en) | 2013-08-16 | 2019-04-09 | Quidel Corporation | Method for species-independent measurement of complement activation in animals |
| ES2796078T3 (es) * | 2013-09-16 | 2020-11-25 | Childrens Hospital Med Ct | Composiciones y métodos para el tratamiento de la microangiopatía trombótica asociada al hsct |
| WO2015070041A1 (en) | 2013-11-08 | 2015-05-14 | Icahn School Of Medicine At Mount Sinai | Methods for monitoring kidney dysfunction |
| WO2016200627A1 (en) | 2015-06-09 | 2016-12-15 | Children's Hospital Medical Center | Dosing algorithm for complement inhibitor |
-
2014
- 2014-09-16 ES ES14843902T patent/ES2796078T3/es active Active
- 2014-09-16 US US14/911,098 patent/US10815296B2/en active Active
- 2014-09-16 JP JP2016542879A patent/JP6654137B2/ja active Active
- 2014-09-16 CA CA2921856A patent/CA2921856A1/en active Pending
- 2014-09-16 EP EP14843902.9A patent/EP3046581B1/en active Active
- 2014-09-16 EP EP20164737.7A patent/EP3750914A1/en active Pending
- 2014-09-16 WO PCT/US2014/055922 patent/WO2015039126A1/en not_active Ceased
-
2019
- 2019-12-25 JP JP2019234471A patent/JP7572777B2/ja active Active
-
2022
- 2022-02-02 JP JP2022014712A patent/JP2022062161A/ja active Pending
-
2024
- 2024-07-24 JP JP2024118532A patent/JP2024133399A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goldshmit et al. | Rapamycin increases neuronal survival, reduces inflammation and astrocyte proliferation after spinal cord injury | |
| Wei et al. | Human umbilical cord-derived mesenchymal stem cells ameliorate perioperative neurocognitive disorder by inhibiting inflammatory responses and activating BDNF/TrkB/CREB signaling pathway in aged mice | |
| Horvatits et al. | Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients | |
| Zhang et al. | Glycyrrhizin administration ameliorates coxsackievirus B3-induced myocarditis in mice | |
| CN1997385B (zh) | 膜联蛋白v用于预防动脉血栓和斑块破裂 | |
| Kong et al. | Renoprotective effect of isoorientin in diabetic nephropathy via activating autophagy and inhibiting the PI3K-AKT-TSC2-mTOR pathway | |
| Wu et al. | Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis | |
| Zhang et al. | Rapamycin protects kidney against ischemia reperfusion injury through recruitment of NKT cells | |
| Wang et al. | Inhibition of Asthma in OVA Sensitized Mice Model by a Traditional Uygur Herb Nepeta bracteata Benth. | |
| Lim et al. | High variability of teicoplanin concentration in patients with continuous venovenous hemodiafiltration | |
| Omar et al. | Hemoperfusion for clinically suspected organophosphate and carbamate poisoning in critically ill patients: A randomized trial | |
| Kunka et al. | Flucytosine pharmacokinetics in a critically ill patient receiving continuous renal replacement therapy | |
| Zou et al. | Iron-Quercetin complex enhances mesenchymal stem cell-mediated HGF secretion and c-Met activation to ameliorate acute kidney injury through the prevention of tubular cell apoptosis | |
| WO2020018343A1 (en) | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products | |
| Li et al. | Berbamine, a bioactive alkaloid, suppresses equine herpesvirus type 1 in vitro and in vivo | |
| Price et al. | Protein-energy wasting in chronic kidney disease: mechanisms responsible for loss of muscle mass and function | |
| US20220395540A1 (en) | Treatment of covid-19 lung injury using umbilical cord plasma based compositions | |
| WO2008047880A1 (en) | Therapeutic agent for rheumatoid arthritis | |
| Kim et al. | Comparison of the medium cutoff dialyzer and postdilution hemodiafiltration on the removal of small and middle molecule uremic toxins | |
| Papp et al. | Pharmacokinetics of cefovecin in squirrel monkey (Saimiri sciureus), rhesus macaques (Macaca mulatta), and cynomolgus macaques (Macaca fascicularis) | |
| US20200230115A1 (en) | Methods of treating influenza-associated viral pneumonia | |
| Kasuya et al. | Clearance efficacy of autoantibodies in double filtration plasmapheresis for pemphigus foliaceus. | |
| Mehrab-Mohseni et al. | Legalon-SIL downregulates HCV core and NS5A in human hepatocytes expressing full-length HCV | |
| Zhang et al. | Upregulation of rat renal cortical organic anion transporter (OAT1 and OAT3) expression in response to ischemia/reperfusion injury | |
| Wang et al. | Lipid microsphere‐coated PGE1 improves peritoneal transport and reduces inflammation in peritoneal dialysis: A randomized clinical pilot trial |